The Nascent Industry Taking On an $8.5 Trillion Juggernaut!

For years, psychedelic mushrooms have been demonized. But today, those attitudes are changing. SPECIAL OPPORTUNITIES [The Oxford Club Special Opportunities]( [Matt Benajmin] Note from Senior Macroeconomic Analyst Matt Benjamin: Trends Expert Matthew Carr knows the ins and outs of all the current and upcoming trends in the markets. He's recently been focusing his attention on the healthcare industry... and for more reasons than the obvious. Matthew sees some major innovations heading our way beyond any COVID-19 vaccine. You might remember how the cannabis industry exploded onto the scene a few years ago... well, [Matthew sees something bigger coming our way]( and it's something that could revolutionize the $8 trillion healthcare industry. He's got an entire video presentation to tell you all about it. [Just click here for all the details]( - I know you're not going to want to miss this one. The Nascent Industry Taking On an $8.5 Trillion Juggernaut! Matthew Carr, Trends Expert, The Oxford Club The global healthcare industry is a juggernaut with a capital "J." And I'm not talking about the gem-empowered supervillain who routinely squares off against Deadpool, Hulk, Spider-Man, the X-Men and pretty much everyone in the Marvel Universe who gets in his way. But the healthcare industry is nonetheless undeniably enormous... and only getting more so. In 2018, the industry was worth $8.45 trillion. By 2022, thanks to the graying of America and the rapidly aging world population, global healthcare spending is projected to top $10 trillion. In most developed countries, it accounts for roughly 10% of gross domestic product (GDP). In countries where healthcare is more expensive, like the U.S., it's closer to 20% of GDP. Healthcare is one of the largest and fastest-growing industries in the world. And that's why investors need to sit up and pay attention, because it is about to get disrupted. The Other 21st-Century Solution Over the years, I've discussed how new technologies are going to create massive opportunities in healthcare. These disrupters are creating waves as we speak. For example, the Internet of Things is poised to reduce healthcare costs and inefficiencies by as much as $100 billion per year. Precision medicine is on the path to topping $119 billion as we enter a new era of personalized treatment. Telemedicine is skyrocketing. Artificial intelligence and surgical robots are here. These are sci-fi, 21st-century solutions to healthcare. But the technological advancements over the last few decades have allowed another set of disrupters to emerge from the shadows. These are things humanity has turned to for millennia, though we're only now beginning to scratch the surface of how and why they work, and what potential they ultimately have. Take cannabis, for instance... Five thousand years ago, the fabled Chinese emperor Shen Nung prescribed cannabis for a laundry list of ailments. In ancient India, it was seen as a gift from the gods. And in De Materia Medica, published in A.D. 70, the Roman physician Pedanius Dioscorides recommended cannabis for earaches and diminished libido. We know it has a wide range of medical uses. Doctors prescribe it to treat chronic pain, sleep disorders, eating disorders, PTSD, anxiety and depression. You name it - marijuana has the potential to help. And up until the 1930s and the rise of "Reefer Madness," cannabis was a valued medicine. But it wasn't until the 1990s that scientists discovered humans had an endocannabinoid system. There is an entire system throughout our bodies hardwired to react to cannabis, which impacts our appetite, memory, energy, stress responses, immune functions, sleep and more. In the couple of decades since, attitudes toward cannabis have started to shift. Though only very recently has cannabis moved from being seen as a dangerous drug to being recognized as a potential miracle worker. In turn, countries have started legalizing marijuana, as we're witnessing here in the U.S. And we know on election night, the number of states greenlighting cannabis use will continue to grow. But there's another nascent pharmaceutical development I believe investors must open their eyes to. Just as they did with cannabis. The $100 Billion Psychedelic Breakthrough Mushrooms have been consumed by humans for eons. Thousands of years ago, The Divine Farmer's Materia Medica - one of the foundational texts of Chinese wellness practices - described the health benefits of fungi. But beyond button, chanterelle, linghzi, porcini and portobello, we all know there's a "magic mushroom" variety as well. The psychedelic kind. These are so ingrained in our collective psyche that I bet we all picture the same image when hearing the words "magic mushrooms" - white stalks with red caps and white spots. The infamous fly agaric, the pedestal for fairies and pixies, is pictured in everything from Alice in Wonderland to The Smurfs. The Celtic druids referred to these mushrooms as the "flesh of the gods" because of their mind-boosting attributes. The Aztecs had their own "flesh of the gods," the teonanácatl mushroom. And it's believed humans have been chomping on hallucinogenic mushrooms since roughly 9000 B.C. But they offer more than just "trips." They are actually a living medicine. Unfortunately, like cannabis, mushrooms were demonized. But like the opinions on cannabis, those attitudes are changing, with states leading the charge on decriminalization, as we rediscover that these mushrooms - and their active compound psilocybin - could be pivotal in treating various mental illnesses. In October 2018, the U.S. Food and Drug Administration gave the thumbs-up to research the use of mushrooms to combat treatment-resistant depression. And it fast-tracked a second psilocybin treatment for depression a year later. In September 2019, Johns Hopkins University unveiled its Center for Psychedelic and Consciousness Research. This will explore using psilocybin to treat opioid addiction, alcohol and nicotine dependency, Lyme disease, PTSD, and more. Last year, Denver, Colorado, and Oakland, California, decriminalized psychedelic mushrooms. This year, Santa Cruz, California, followed suit. And in November, Oregon and Washington, D.C., will vote on measures to do the same. It's now estimated the global market for psilocybin and psychedelic medicine will top $100 billion. And our long history of consuming has real monetary benefits. Typically, it takes a decade and $2.6 billion to develop a prescription drug. But treatments using psilocybin and mushrooms - because of the decades and decades of consumption already documented - could take a lot less time. And right now there are more than a dozen psychedelic clinical trials underway in the U.S. We are on the cusp of a nascent industry that will tackle some of the most devastating diseases and mental health issues on the planet. And it's disrupting one of the largest and fastest-growing industries on Earth - an $8.5 trillion juggernaut. And Silicon Valley legends, billionaire financiers, huge hedge funds, Wall Street and Big Pharma are all taking notice. That means investors must do the same. Here's to high returns, Matthew SPONSORED [These Stocks Priced Around $2 Are Going to Change Human History]( If you're looking for the next major innovation to "emerge from darkness"... These stocks are selling for an average of under $2 per share... And they're about to completely rewrite the course of modern medicine. [The Oxford Club] You are receiving this email because you subscribed to Oxford Club Special Opportunities. Oxford Club Special Opportunities is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Oxford Club Special Opportunities]( | [Unsubscribe]( © 2020 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [1.800.589.3430](#) | International: [+1.443.353.4334](#) | Fax: [1.410.329.1923](#) [Oxfordclub.com]( Your Legal Questions... Answered What is The Oxford Club? The Oxford Club is a financial publisher with a highly rated track record. We deliver unique and well-researched financial and investment ideas to our Members. What do you do? We share our team of experts' industry knowledge and timely insights with our Members so they have the financial literacy and tools needed to build a rich, fulfilling life. We do not provide any personalized financial advice or advocate the purchase or sale of any security or investment for any specific individual. Instead, the information we share is directed toward a larger audience of all subscribed Members. So you'll make me rich? Maybe! But not exactly. Our goal is to provide the research and information required to help you make you rich. Investment markets have inherent risks, and we can't guarantee future profits. Why should I trust you? We offer information based on what we think will provide the most value to our Members. Our business depends on Members' interest in our ideas and satisfaction with their results. We've been around for 30-plus years because our Members have continually chosen to stay with us (many of them for life). We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications before following an initial recommendation. So I can fire my investment advisor? No! Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.